Polyarteritis nodosa and Churg-Strauss syndrome. An internist's view.
Guillevin
L
L
Department of Internal Medicine, Hôpital Avicenne, Université Paris-Nord, Bobigny, France.
Gayraud
M
M
Casassus
P
P
D019268:Antibodies, Antineutrophil Cytoplasmic; D001323:Autoantibodies / Q000097:blood; D015267:Churg-Strauss Syndrome / Q000473:pathology / Q000628:therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D006509:Hepatitis B / Q000188:drug therapy; D006510:Hepatitis B Antibodies / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D010951:Plasma Exchange; D010488:Polyarteritis Nodosa / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D014740:Vidarabine / Q000627:therapeutic use
D019268:Antibodies, Antineutrophil Cytoplasmic; D001323:Autoantibodies; D006510:Hepatitis B Antibodies; D006513:Hepatitis B e Antigens; D003520:Cyclophosphamide; D014740:Vidarabine; D011241:Prednisone